169 related articles for article (PubMed ID: 36539893)
21. Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines.
Peasland A; Wang LZ; Rowling E; Kyle S; Chen T; Hopkins A; Cliby WA; Sarkaria J; Beale G; Edmondson RJ; Curtin NJ
Br J Cancer; 2011 Jul; 105(3):372-81. PubMed ID: 21730979
[TBL] [Abstract][Full Text] [Related]
22. Lamin misexpression upregulates three distinct ubiquitin ligase systems that degrade ATR kinase in HeLa cells.
Muralikrishna B; Chaturvedi P; Sinha K; Parnaik VK
Mol Cell Biochem; 2012 Jun; 365(1-2):323-32. PubMed ID: 22382637
[TBL] [Abstract][Full Text] [Related]
23. RNF126 promotes homologous recombination via regulation of E2F1-mediated BRCA1 expression.
Wang Y; Deng O; Feng Z; Du Z; Xiong X; Lai J; Yang X; Xu M; Wang H; Taylor D; Yan C; Chen C; Difeo A; Ma Z; Zhang J
Oncogene; 2016 Mar; 35(11):1363-72. PubMed ID: 26234677
[TBL] [Abstract][Full Text] [Related]
24. Anti-tumor activity of the ATR inhibitor AZD6738 in HER2 positive breast cancer cells.
Kim HJ; Min A; Im SA; Jang H; Lee KH; Lau A; Lee M; Kim S; Yang Y; Kim J; Kim TY; Oh DY; Brown J; O'Connor MJ; Bang YJ
Int J Cancer; 2017 Jan; 140(1):109-119. PubMed ID: 27501113
[TBL] [Abstract][Full Text] [Related]
25. SIAH ubiquitin ligases regulate breast cancer cell migration and invasion independent of the oxygen status.
Adam MG; Matt S; Christian S; Hess-Stumpp H; Haegebarth A; Hofmann TG; Algire C
Cell Cycle; 2015; 14(23):3734-47. PubMed ID: 26654769
[TBL] [Abstract][Full Text] [Related]
26. The ubiquitin ligase RNF126 regulates the retrograde sorting of the cation-independent mannose 6-phosphate receptor.
Smith CJ; McGlade CJ
Exp Cell Res; 2014 Jan; 320(2):219-32. PubMed ID: 24275455
[TBL] [Abstract][Full Text] [Related]
27. A molecular triage process mediated by RING finger protein 126 and BCL2-associated athanogene 6 regulates degradation of G
Kamikubo K; Kato H; Kioka H; Yamazaki S; Tsukamoto O; Nishida Y; Asano Y; Imamura H; Kawahara H; Shintani Y; Takashima S
J Biol Chem; 2019 Oct; 294(40):14562-14573. PubMed ID: 31371451
[TBL] [Abstract][Full Text] [Related]
28. A novel RING-type ubiquitin ligase breast cancer-associated gene 2 correlates with outcome in invasive breast cancer.
Burger AM; Gao Y; Amemiya Y; Kahn HJ; Kitching R; Yang Y; Sun P; Narod SA; Hanna WM; Seth AK
Cancer Res; 2005 Nov; 65(22):10401-12. PubMed ID: 16288031
[TBL] [Abstract][Full Text] [Related]
29. RNF144A functions as a tumor suppressor in breast cancer through ubiquitin ligase activity-dependent regulation of stability and oncogenic functions of HSPA2.
Yang YL; Zhang Y; Li DD; Zhang FL; Liu HY; Liao XH; Xie HY; Lu Q; Zhang L; Hong Q; Dong WJ; Li DQ; Shao ZM
Cell Death Differ; 2020 Mar; 27(3):1105-1118. PubMed ID: 31406303
[TBL] [Abstract][Full Text] [Related]
30. Inhibiting Wee1 and ATR kinases produces tumor-selective synthetic lethality and suppresses metastasis.
Bukhari AB; Lewis CW; Pearce JJ; Luong D; Chan GK; Gamper AM
J Clin Invest; 2019 Mar; 129(3):1329-1344. PubMed ID: 30645202
[TBL] [Abstract][Full Text] [Related]
31. Anti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancer.
Lee J; Lim B; Pearson T; Choi K; Fuson JA; Bartholomeusz C; Paradiso LJ; Myers T; Tripathy D; Ueno NT
Breast Cancer Res Treat; 2019 Jun; 175(2):339-351. PubMed ID: 30826934
[TBL] [Abstract][Full Text] [Related]
32. UV-induced activation of ATR is mediated by UHRF2.
Hanaki S; Habara M; Shimada M
Genes Cells; 2021 Jun; 26(6):447-454. PubMed ID: 33848395
[TBL] [Abstract][Full Text] [Related]
33. ATR/Chk1/Smurf1 pathway determines cell fate after DNA damage by controlling RhoB abundance.
Wang M; Guo L; Wu Q; Zeng T; Lin Q; Qiao Y; Wang Q; Liu M; Zhang X; Ren L; Zhang S; Pei Y; Yin Z; Ding F; Wang HR
Nat Commun; 2014 Sep; 5():4901. PubMed ID: 25249323
[TBL] [Abstract][Full Text] [Related]
34. ATR mediates cisplatin resistance in 3D-cultured breast cancer cells via translesion DNA synthesis modulation.
Gomes LR; Rocha CRR; Martins DJ; Fiore APZP; Kinker GS; Bruni-Cardoso A; Menck CFM
Cell Death Dis; 2019 Jun; 10(6):459. PubMed ID: 31189884
[TBL] [Abstract][Full Text] [Related]
35. Ataxia telangiectasia and Rad3-related inhibitors and cancer therapy: where we stand.
Mei L; Zhang J; He K; Zhang J
J Hematol Oncol; 2019 Apr; 12(1):43. PubMed ID: 31018854
[TBL] [Abstract][Full Text] [Related]
36. Tumor cell-derived exosome RNF126 affects the immune microenvironment and promotes nasopharyngeal carcinoma progression by regulating PTEN ubiquitination.
Yu C; Xue B; Li J; Zhang Q
Apoptosis; 2022 Aug; 27(7-8):590-605. PubMed ID: 35717659
[TBL] [Abstract][Full Text] [Related]
37. Contribution of ATM and ATR to the resistance of glioblastoma and malignant melanoma cells to the methylating anticancer drug temozolomide.
Eich M; Roos WP; Nikolova T; Kaina B
Mol Cancer Ther; 2013 Nov; 12(11):2529-40. PubMed ID: 23960094
[TBL] [Abstract][Full Text] [Related]
38. Deubiquitinase ubiquitin-specific protease 9X regulates the stability and function of E3 ubiquitin ligase ring finger protein 115 in breast cancer cells.
Lu Q; Lu D; Shao ZM; Li DQ
Cancer Sci; 2019 Apr; 110(4):1268-1278. PubMed ID: 30689267
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of Ataxia-Telangiectasia Mutated and RAD3-Related (
Combès E; Andrade AF; Tosi D; Michaud HA; Coquel F; Garambois V; Desigaud D; Jarlier M; Coquelle A; Pasero P; Bonnefoy N; Moreaux J; Martineau P; Del Rio M; Beijersbergen RL; Vezzio-Vie N; Gongora C
Cancer Res; 2019 Jun; 79(11):2933-2946. PubMed ID: 30987998
[TBL] [Abstract][Full Text] [Related]
40. Targeting ataxia telangiectasia-mutated- and Rad3-related kinase (ATR) in PTEN-deficient breast cancers for personalized therapy.
Al-Subhi N; Ali R; Abdel-Fatah T; Moseley PM; Chan SYT; Green AR; Ellis IO; Rakha EA; Madhusudan S
Breast Cancer Res Treat; 2018 Jun; 169(2):277-286. PubMed ID: 29396668
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
